Correction: Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study

GLOBAL HEART

CORRECTION

DORAIRAJ PRABHAKARAN
KAVITA SINGH
DIMPLE KONDAL
LANA RASPAIL
BISHAV MOHAN
TORU KATO
NIZAL SARRAFZADEGAN
SHAMIM HAYDER TALUKDER
SHAHIN AKTER
MOHAMMAD ROBED AMIN
FASTONE GOMA
JUAN GOMEZ-MESA
NTOBEKO NTUSI
FRANCISCA INOFOMOH
SURENDER DEORA
EVGENII PHILIPPOV
ALLA SVAROVSKAYA
ALEXANDRA KONRADI
AURELIO PUENTES
OKECHUKWU S. OGAH
BOJAN STANETIC
AURORA ISSA
FRIEDRICH THIENEMANN
DAFSAH JUZAR
EZEQUIEL ZAIDEL
SANA SHEIKH
DIKE OJJI
CAROLYN S. P. LAM
JUNBO GE
AMITAVA BANERJEE
L. KRISTIN NEWBY
ANTONIO LUIZ P. RIBEIRO
SAMUEL GIDDING
FAUSTO PINTO
PABLO PEREL
KAREN SLIWA
ON BEHALF OF THE WHF COVID-19 STUDY COLLABORATORS

*Author affiliations can be found in the back matter of this article

ubiquity press

This article has been corrected here: https://doi.org/10.5334/gh.1128

CORRESPONDING AUTHOR:
Dorairaj Prabhakaran
Public Health Foundation India, Centre for Chronic Disease Control, World Heart Federation, London School of Hygiene & Tropical Medicine, GB
dprabhakaran@phfi.org

KEYWORDS:
Cardiology; Cardiovascular Health; Global Health; Covid-19

TO CITE THIS ARTICLE:
Prabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T, Sarrafzadegan N, Talukder SH, Akter S, Amin MR, Goma F, Gomez-Mesa J, Ntusi N, Inofomoh F, Deora S, Philippov E, Svarovskaya A, Konradi A, Puentes A, Ogah OS, Stanetic B, Issa A, Thienemann F, Juzar D, Zaidel E, Sheikh S, Ojji D, Lam CSP, Ge J, Banerjee A, Newby LK, Ribeiro ALP, Gidding S, Pinto F, Perel P, Sliwa K, On Behalf of the WHF COVID-19 Study Collaborators. Correction: Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. *Global Heart*. 2022; 17(1): 79. DOI: https://doi.org/10.5334/gh.1167

ABSTRACT

This article details a correction to: Prabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T, et al. Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. *Global Heart*. 2022; 17(1): 40. DOI: http://doi.org/10.5334/gh.1128.

COVID-SYMPTOMS AND VITAL SIGNS	OVERALL	SURVIVORS	IN-HOSPITAL DEATHS	POST DISCHARGE 30-DAY DEATHS
	N (%)	N (%)	N (%)	N (%)
Diagnosed by using RT-PCR	5050 (95.0)	4299(85.1)	644(12.8)	107(2.1)
Median time from symptom onset to admission (IQR) in minutes	5 (3–8)	5 (3–8)	5 (3–8)	4 (2–7)
History of self-reported fever	3526 (66.4)	3002 (85.1)	459 (13.0)	65 (1.9)
Cough	3624 (68.2)	3087 (85.2)	472 (13.0)	65 (1.8)
Dyspnoea OR Tachypnoea	3308 (62.3)	2689 (81.3)	534(16.1)	85 (2.6)
Heart rate (beats/min), mean (SD)	92.1 (17.8)	91.2 (17.0)	96.9 (21.6)	95.7 (17.3)
Bradycardia (HR<60bpm) mean (SD)	101 (1.9)	85 (84)	15 (15)	1 (1)
Tachycardia (HR>100bpm) mean (SD)	1409 (26.5)	1103 (78)	265 (19)	41 (3)
Systolic BP (mmHg), mean (SD)	128.8 (20.9)	128.7 (19.9)	129.7 (25.4)	129.7 (26.3)
Diastolic BP (mmHg), mean (SD)	78.2 (13.0)	78.5 (12.5)	76.4 (15.4)	77.0 (14.9)
Shortness of Breath (SOB)				
SOB < 100m	1336 (25.5)	1047(78.4)	252 (18.8)	37 (2.8)
SOB 100–500m	479 (9.1)	364(76.0)	96 (20.0)	19 (4.0)
SOB > 500m	225 (4.3)	203(90.2)	15 (6.7)	7 (3.1)
Co-morbidities (Cardiovascular)				
Hypertension	2511 (47.3)	2060 (82.0)	398 (16.0)	53 (2.0)
Diabetes	1700 (32.0)	1346 (79.2)	306 (17.8)	48 (3.0)
Coronary artery disease	580 (10.9)	446 (76.9)	103 (17.8)	31 (5.3)
Heart Failure	290 (5.5)	238 (82.1)	45 (15.5)	7 (2.4)
Stroke	197 (3.7)	159 (80.7)	28 (14.2)	10 (5.1)
Atrial Fibrillation	159 (3.0)	134 (84.3)	22 (13.8)	3 (1.9)
Peripheral vascular disease	106 (2.0)	85 (80.2)	18 (17.0)	3 (2.8)
Cardiomyopathies	60 (1.1)	53 (88.3)	6 (10.0)	1 (1.7)
Rheumatic Heart Disease	56 (1.1)	49 (87.5)	7 (12.5)	0 (0)
Chagas disease	36 (0.7)	34 (94.4)	2 (5.6)	0 (0)
Congenital heart disease	182 (3.4)	166 (91.2)	9 (4.9)	7 (3.8)
Valvular disease	118 (2.2)	94 (79.7)	21(17.8)	3 (2.5)
Co-morbidities (Non-Cardiovascular)				
Chronic kidney disease	404 (7.6)	299 (74.0)	86 (21.3)	19 (4.7)
Chronic pulmonary disease	208 (3.9)	160 (76.5)	44 (21.1)	5 (2.4)
Asthma	219 (4.1)	200 (91.3)	18 (8.2)	1 (0.5)
Chronic Immunosuppression	136 (2.6)	110 (80.9)	25 (18.4)	1 (0.7)
HIV	71 (1.3)	62 (87.3)	6 (8.5)	3 (4.2)
Tuberculosis	56 (1.1)	49 (87.5)	7 (12.5)	0 (0)
Cancer on chemotherapy	114 (2.1)	90 (78.9)	20 (17.5)	4 (3.6)
Renal replacement therapy	62 (1.2)	45 (72.6)	16 (25.8)	1 (1.6)
Previous organ transplant	45 (0.8)	38 (84.8)	7 (15.6)	0 (0)

Table 2b COVID-19 symptoms and comorbidities among study participants.

Rt-PCR = Reverse Transcription Polymerase Chain Reaction; SD = standard deviation; IQR = Inter quartile range; BP = blood pressure; SOB = Shortness of breath; HIC = high income countries; UMIC = upper middle-income countries; LMIC = lower middle-income countries; LIC = low-income countries; HIV = Human immunodeficiency virus. Row percentage reported for all categorical variables.

	OVERALL N (%)	SURVIVORS N (%)	IN-HOSPITAL DEATHS N (%)	POST DISCHARGE 30-DAY DEATHS N (%)	P-VALUE FOR DIFFERENCE
ECG data (N = 3490)					
Atrial fibrillation (yes)	131 (2.5)	97 (2.1)	31 (4.5)	3 (2.5)	0.003
T-wave changes (yes)	774 (14.6)	593 (13.1)	153 (22.4)	28 (23.7)	<0.001
QT/QTC duration, median (IQR)	419.0 (331.5, 447.0)	415.5 (259.0, 445.0)	428.0 (360.0, 457.0)	448.0 (413.5, 467.0)	<0.001
ECHO findings (Median, IQR) (N = 259)					
Ejection fraction 1. Teicholz (EF1),	59.1 (49.0, 64.0)	60.0 (52.0, 64.0)	55.0 (45.0, 64.0)	59.0 (59.0, 60.0)	0.23
Ejection fraction 2. Visual estimations (EF2),	55.0 (45.0, 60.0)	55.0 (45.0, 60.0)	51.5 (45.0, 59.0)	50.0 (35.0, 55.0)	0.082
Right ventricular function					0.002
Mildly/severely abnormal	47 (0.9)	28 (59.1)	18 (38.6)	1 (2.3)	
Laboratory parameters (median, IQR) (N = 4330)					
Hemoglobin, mmol/L	7.9 (7.1, 8.8)	8.0 (7.1, 8.8)	7.8 (6.6, 8.7)	7.5 (6.5, 8.4)	<0.001
WBC count, ×10^9/L	4.7 (0.0, 8.4)	5.1 (0.0, 8.5)	0.018 (0.009, 7.5)	0.0184 (0.009, 6.9)	<0.001
Platelets, 10^3/µL	230.5 (168.0, 336.0)	233.0 (170.0, 342.0)	219.0 (157.0, 306.0)	228.0 (154.0, 425.0)	<0.001
ALT/SGPT, µmol/(s•L)	0.60 (0.38, 0.97)	0.58 (0.38, 0.95)	0.65 (0.40, 1.11)	0.63 (0.41, 1.09)	0.003
AST/SGOT, µmol/(s•L)	0.67 (0.47, 1.05)	0.65 (0.45, 1.00)	0.79 (0.52, 1.37)	0.82 (0.53, 1.30)	<0.001
Creatinine-conversion, µmol/L	87.5 (70.6, 113.2)	85.0 (69.0, 107.0)	99.9 (74.3, 150.3)	104.3 (82.2, 195.4)	<0.001
Sodium, mmol/L	137.0 (134.0, 140.0)	137.0 (134.0, 140.0)	136.3 (133.0, 140.0)	136.0 (133.0, 139.0)	0.10
Potassium, mmol/L	4.2 (3.8, 4.7)	4.2 (3.8, 4.6)	4.3 (3.8, 4.9)	4.5 (4.1, 5.0)	<0.001
CRP, mg/L	53.8 (17.4, 110.7)	48.0 (15.7, 100.0)	93.2 (40.2, 174.0)	82.9 (21.5, 156.1)	<0.001
ESR, mm/hr	43.0 (25.0, 67.0)	41.0 (24.0, 65.0)	52.0 (34.0, 81.0)	53.0 (40.0, 79.0)	<0.001
Troponin, ng/mL	1.0 (0.1, 9.0)	1.0 (0.1, 9.0)	0.1 (0.037, 11.0)	20.0 (2.9, 32.0)	0.007
Troponin T, pg/mL	9.0 (0.5, 24.9)	8.0 (0.6, 20.0)	21.0 (5.5, 64.5)	0.123 (0.014, 16.0)	<0.001
BNP, pmol/L	7.8 (1.5, 28.1)	6.0 (1.2, 21.4)	16.0 (5.1, 49.4)	19.9 (2.2, 44.1)	<0.001
NT-proBNP, pmol/L	60.1 (12.1, 254.4)	46.7 (10.3, 224.2)	110.7 (34.3, 415.5)	505.5 (285.5, 1641.0)	<0.001
CK-Mb, ukat/L,	0.24 (0.017, 13.0)	0.23 (0.017, 13.0)	0.47 (0.034, 19.0)	0.049 (0.017, 0.613)	0.001
Total cholesterol, mmol/L	4.0 (3.1, 5.0)	4.2 (3.4, 5.2)	3.4 (2.7, 4.3)	3.9 (2.5, 4.4)	<0.001
HbA1c, %	6.9 (6.1, 8.5)	6.9 (6.1, 8.5)	7.0 (6.2, 8.4)	6.4 (5.9, 9.7)	0.80
D-dimer, mg/FEU/L	1.0 (0.4, 4.4)	0.9 (0.4, 3.9)	1.8 (0.7, 4.8)	2.5 (1.2, 26.5)	<0.001
Ferritin, µg/L	514.1 (225.3, 1001.9)	476.0 (197.5, 962.0)	687.7 (350.3, 1365.2)	656.6 (392.0, 1068.0)	<0.001
IL-6, pg/mL	25.2 (8.7, 64.7)	21.6 (7.0, 52.0)	65.8 (21.9, 125.0)	36.0 (17.6, 133.5)	<0.001
Urea (BUN), mmol/L,	8.5 (5.5, 14.6)	7.7 (5.2, 12.9)	13.9 (7.9, 23.8)	17.0 (10.4, 28.2)	<0.001
PT (seconds)	13.4 (12.0, 15.9)	13.3 (12.0, 15.6)	13.9 (12.1, 16.7)	13.2 (11.7, 16.7)	0.012
INR ratio	1.1 (0.9, 1.25)	1.1 (0.9, 1.23)	1.1 (0.96, 1.32)	1.1 (0.0119, 1.32)	0.015

Table 3 ECG, ECHO, and laboratory findings among COVID-19 patients at admission.

IQR = interquartile range; mmol/L millimoles per liter; mg/L = milligrams per liter.

THE COLLABORATOR LIST

Four collaborators were inadvertently missed off the original list: L. Tetteh Appiah, Nabil Varwani, Lucky Rose Adika, and Humphrey Robert Guya.

The full, corrected contributor list is:

Rio de Janeiro, Brazil, Instituto Nacional de Cardiologia: A. Issa, H. Cramer, C. Lamas, M. Paulino, V. Belidio, L. Sabioni, **Buenos Aires, Argentina**, Hospital de Clinicas of the University: R. Pérez de la Hoz, J. Martin Aladio, M. Matsudo, S. Swieszkowski, A. Perez de la Hoz,

Buenos Aires, Argentina, Sanatorio Güemes: E. J. Zaidel, J. Perea, M. Ariel Oliva, N. Carboni Martinez, N. Bisso, L. Gheco, **Dhaka, Bangladesh**, Dhaka Medical College Hospital: S. Talukder, S.Akter, M. Robed Amin, M. Ahmedul Kabir, M. Khairul Islam, M. Mohiuddin Sharif, K. Fayzus Salahin, S. Hossain, **Dhaka, Bangladesh**, Kuwait Bangladesh Friendship Govt. Hospital: A. Rahim, K. M. Rubayet Anwar, S. Sajmin Siddiqa, M. Rahman, A. Hossain, **Dhaka, Bangladesh**, Bangladesh Specialized Hospital: A. Wadud Chowdhury, M. Mohiuddin Ahmed, M. Mushfiqur Rahman, U. F. Sultana, Srpska, **Bosnia and Herzegovina**, University Clinical Center Republic of Srpska: B. Stanetic, I. Ovcina, B. Dujakovic, R. Tamburic, D. Vulic, R. Skrbic, **Temuco, Chile**, Hospital Dr. Hernán Henríquez Aravena: P. Figuero, F. La, C. Acs, S. Saavedra Bogota, **Colombia**, Clinica de Occidente: J Lugo-Peña, M. Ángel Zuleta, **Cali, Colombia**, Fundacion Valle del Lili: J. Esteban Gomez Mesa, S. Stephania Galindo-Coral, Maria Claudia Montes, **Tbilisi, Georgia**, High Technology Medical Centre: University Clinic (HTMC), K. Chelidze, I. Mamatsashvli, **Kumasi, Ghana**, Komfo Anokye Teaching Hospital: L Tetteh Appiah, Y. Hardy, J. Hutton, **Accra, Ghana**, Military Hospital: A. Toppar, **Ludhiana, India**, Dayanand Medical College Hospital: B. Mohan, M. Mennen, S. Singla, K. Jain, Ankush, **Hyderabad, India**, Apollo Hospital: V. Ram, G. Praveen Kumar, K. Subba Reddy, B. V. K. S. Sowmya, M. Rebecca, **Hyderabad, India**, Apollo Medical College: Jubilee Hills, S. Kuruvada, A. Nimmagadda, A. Begum, **Jodhpur, India**, P. Bhardwaj, J. Charan, S. Deora, D. Sharma, **New Delhi, India**, All India Institute Of Medical Sciences (AIIMS): N Naik, N Rai **Jakarta, Indonesia**, National Cardiovascular Center harapan Kita Hospital: D. Juzar, I Firdaus, B. Putra, M. Rayhan, **Isfahan, Iran**, Amin Hospital: Ladan Sadeghian, N. Sarrafzadegan, Khorshid hospital, **Isfahan, Iran**, Mohammad Hashemi, **Kyoto, Japan**, Kyoto Medical Center: K. Hasegawa, Y. Iida, **Tokyo, Japan**, Kitasato University School of Medicine: J. Ako, R. Kameda, **Tochigi, Japan**, NHO Tochigi Medical Center: T. Kato, **Mombasa, Kenya**, Coast General Teaching and Referral Hospital: E. Ogola, K. Mwazo, V. Vaghela, S. Mohamed, A. Abeid, V. Mumbo, M. Ali Mohamed, A. Ikbal Varvani, M. Omar, V. Karegi, B. Nduati, Swaleh, E. Gacheri, D. Anyanga, S. M. Mohamed, E. Gacheri Riungu, D. Anyanga, Nabil Varwani, **Mombasa, Kenya**, The Mombasa Hospital: S. Mohamed, E. Gacheri Riungu, D. Anyanga, J. Kamuyu Muriuki, K. Rose, Lucky Rose Adika, Humphrey Robert Guya, **Guanajuato, Mexico**, ISSSTE Clínica Hospital de Guanajuato: A. Puentes Puentes, **Lagos Nigeria**, College of Medicine University of Lagos, A. Mbakwem, **Ibadan, Nigeria**, University College Hospital: O. Ogah, O. Adekanmbi, O. Adebayo, Y. Oyebisi, O. Makinde, O.A. Orimolade, O. Makinde, S. Alabi, **Sagamu, Nigeria**, Olabisi Onabanjo University Teaching Hospital: F. Inofomoh, Ranti Familoni, Abimbola Olaitan, Victor Ayeni, Boluwatife Egbetola, **Sindh, Pakistan**, Tabba Heart Institute: S. Sheikh, H. Khan, Z. Ahmed, S. F. Ali, R. Malik, **Lisbon, Portugal**, University Hospital Sta Maria: F. Pinto, D. Caldeira, S. Braz, J. Agostinho, J. Brito, H. Barbacena, F. Parlato, C. Carreiro, R. Soares, C. Gomes, A. Pinto Sousa, M. José Pires, **St. Petersburg, Russia**, Almazov National Medical Research Centre: A. Konradi, Z. Kobalava, Y. Yudina, M. Ionov, S. Verbilo, Y. Lavrishcheva, S. Bondar, Y. Khruleva **Moscow, Russia, RUDN University**, City clinical hospital named Vinogradov: L. Contselidze, Y. Khruleva, **Kazan, Russia**, Kazan Clinical Hospital, A. Galyavich, Z. Kim, **Tomsk, Russia**, Tomsk National Research Medical Centre, Asinovskaya Regional Hospital: A. Svarovskaya, A. Kuznetsova, **Ryazan, Russia**, Ryazan State Medical University, Ryazan Emergency Hospital: E. Philippov, **Cape Town, South Africa**, Groote Schuur Hospital: N. A. B. Ntusi, L. Chinhoyi, O. Briton, C. Viljoen, K. Sliwa, P. Singh, S. Mazondwa, M. Mennen, N. Williams, **Khartoum, Sudan**, Fedail Hospital: A. Suliman, **Zurich, Switzerland**, University Hospital of Zurich Hospital: F. Thienemann, V. Rossi, T. Studer, **Atlanta, United States**, A. Quyyumi, M. Prasad, D. Braun, **Lusaka, Zambia**, Levy Mwanawasa University Hospital: F. Goma, N. Mumba. ISSSTE Clínica Hospital de Guanajuato: J. E. Luna Cárdenas, G. Sánchez Loza.

NECESSARY REWORDING FOR CLARITY

Throughout the article, some sentences required rewording:

1. In the '*Data Collection*' section:

Each hospital provided the following information at the beginning of the study: estimated size of population served, total number of beds, number of intensive care unit (ICU) beds, number of ventilators, number of cardiologists, availability of echocardiogram (ECG) and advanced care interventional and diagnostic capability (e.g., extracorporeal membrane oxygenation [ECMO], echocardiography [ECHO]), and number of COVID-19 patients admitted in the previous month.

Becomes:

Each hospital provided the following information at the beginning of the study: estimated size of population served, total number of beds, number of intensive care unit (ICU) beds, number of ventilators, number of specialists, availability of echocardiogram (ECG) and advanced care interventional and diagnostic capability (e.g., extracorporeal membrane oxygenation [ECMO], echocardiography [ECHO]), and number of COVID-19 patients admitted in the previous month.

2. In 'Ethical Considerations' the following sentence was added: 'Mandated national regulatory clearances were also obtained.'

3. In 'Results':

Non-survivors more often presented with significantly higher heart rate, lower diastolic blood pressures, shortness of breath and more frequently had hypertension, diabetes, coronary heart disease, atrial fibrillation, rheumatic heart disease, Chagas disease, valvular disease, and chronic kidney disease (Table 2b).

Becomes:

Non-survivors more often presented with significantly higher heart rate, lower diastolic blood pressures, shortness of breath and more frequently had hypertension, diabetes, coronary artery disease, stroke, chronic kidney disease, chronic pulmonary disease, asthma and renal replacement therapy (Table 2b).

4. Further on in the same section, 'ECG examinations (n = 3497 patients; 65.8%) indicated that 2.5% had atrial fibrillation' was corrected to 'ECG examinations (n = 3490 patients; 65.8%) indicated that 2.5% had atrial fibrillation'.

5. In the 'Discussion' section, the following passage was reworded from:

Our analysis demonstrated a greater rate of in-hospital deaths, post discharge 30-day deaths and MACE among Hispanics, and Asian populations compared to Caucasians. Higher prevalence of comorbidities such as hypertension, diabetes, renal disease and obesity among Asians, Hispanics, and other populations (such as Blacks and Middle Eastern populations) may play a role in the increased mortality and MACE in our cohort of COVID-19 patients.

To:

Our analysis demonstrated a greater rate of in-hospital deaths, and post discharge 30-day deaths among Hispanics, Asian, Blacks and Middle Eastern populations compared to Caucasians. Higher prevalence of comorbidities such as hypertension, diabetes, renal disease and obesity among Asians, Hispanics, Blacks and Middle Eastern populations may play a role in the increased mortality and MACE in our cohort of COVID-19 patients.

6. In 'Conclusions', the following sentence: 'The key predictors of mortality or MACE outcomes were older age (≥60 years), male sex, Asian/Hispanic/Black ethnicity, pre-existing coronary heart disease, diabetes, renal disease, severe infection of COVID-19 requiring ICU admission, oxygen therapy and higher respiratory rates, but no significant association was found with hypertension or RAAS inhibitors.' Was corrected by removing 'or MACE outcomes'.

7. In the 'Steering Committee' section, Karen Sliwa (study Co-PI), Dorairaj Prabhakaran (Study Co-PI), Pablo Perel (co-PI), should all have had the same role title of 'Study Co-PI'.

ACKNOWLEDGEMENTS

Dr. Kavita Singh is supported by the National Institutes of Health, Fogarty International Centre, USA; Emerging Global Leader grant award number: 1 K43 TW011164. Dr Ribeiro is supported in part by Brazilian Agencies CNPq (310679/2016-8 and 465518/2014-1), by FAPEMIG (PPM-00428-17) and CAPES (88887.507149/2020-00). Karen Sliwa is supported by the Hippocrate Foundation and the Medical Research Council South Africa.

COMPETING INTERESTS

The authors have no competing interests to declare.

Sana Sheikh
Department of clinical Research, Tabba Heart Institute. ST-1, block 2, Federal B area, Karachi, PK

Dike Ojji
Department of Medicine, Faculty of Clinical Sciences, University of Abuja, and University of Abuja Teaching Hospital, NG

Carolyn S. P. Lam
National Heart Center Singapore and Duke-National University of Singapore, SG; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, NL

Junbo Ge
Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, CN

Amitava Banerjee
University College London, GB

L. Kristin Newby
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, US

Antonio Luiz P. Ribeiro
Cardiology Service and Telehealth Center, Hospital das Clínicas, and Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, BR

Samuel Gidding
World Heart Federation, Geneva, CH

Fausto Pinto
Santa Maria University Hospital, CAML, CCUL, Faculdade de Medicina da Universidade de Lisboa, Lisbon, PT

Pablo Perel orcid.org/0000-0002-2342-301X
Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, World Heart Federation, CH

Karen Sliwa orcid.org/0000-0002-8272-0911
Cape Heart Institute, Department of Medicine & Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, ZA; World Heart Federation, CH

REFERENCE

1. **Prabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T,** et al. Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. *Global Heart*. 2022; 17(1): 40. DOI: https://doi.org/10.5334/gh.1128

TO CITE THIS ARTICLE:
Prabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T, Sarrafzadegan N, Talukder SH, Akter S, Amin MR, Goma F, Gomez-Mesa J, Ntusi N, Inofomoh F, Deora S, Philippov E, Svarovskaya A, Konradi A, Puentes A, Ogah OS, Stanetic B, Issa A, Thienemann F, Juzar D, Zaidel E, Sheikh S, Ojji D, Lam CSP, Ge J, Banerjee A, Newby LK, Ribeiro ALP, Gidding S, Pinto F, Perel P, Sliwa K, On Behalf of the WHF COVID-19 Study Collaborators. Correction: Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. *Global Heart*. 2022; 17(1): 79. DOI: https://doi.org/10.5334/gh.1167

Submitted: 03 October 2022
Accepted: 03 October 2022
Published: 31 October 2022

COPYRIGHT:
© 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.

Global Heart is a peer-reviewed open access journal published by Ubiquity Press.